
Article content
A drug used to treat a rare form of muscular dystrophy will no longer be sold in Canada, leaving some B.C. families anxious about their children’s’ futures as an alternative drug is far more expensive and not yet funded by the province.
Article content
Duchenne muscular dystrophy, a rare genetic disorder that weakens the muscles and usually targets boys, is treated with a corticosteroid drug called Calcort (deflazacort). But the German company that manufactures the drug says it will discontinue it in Canada because of manufacturing and supply chain issues.
Article content
Article content
Advertisement 1
Story continues below
Article content
Xediton Pharmaceuticals, the Canadian distributor of deflazacort, says existing inventory is estimated to last until the spring, Defeat Duchenne Canada recently announced. The national charity says it is working with Health Canada to explore potential alternative sources of the drug and the regulatory steps needed to support access.
Article content
Article content
Health Canada recently approved an alternative steroid drug called vamorolone, but it hasn’t been approved for funding in B.C. Vamorolone is very expensive, costing $131,400 a year, according to Canada’s Drug Agency, compared to just over $1,000 a year for deflazacort.
Article content
Leanna Booth, a Comox Valley resident, said her five-year-old son Lochlan has been receiving vamorolone through a federal program that grants special access to a drug undergoing approval.
Article content
When “Locky” was three years old, he began falling down all the time. The family had him tested and eventually learned he had Duchenne. He was put on deflazacort, which helped stop him from falling down, but caused what Booth described as dreadful mood swings.
Article content

Article content
Within a week of being on vamorolone, the mood swings stopped and he didn’t fall down.
Article content
Advertisement 2
Story continues below
Article content
So now the family is stressed because if deflazacort is taken away as an option, and vamorolone isn’t funded, then they won’t have access to a stable steroid treatment, which they need him to be on to take part in clinical trials for other treatments.
Article content
Read More
Article content
With Duchenne, muscles weaken day by day. Booth said they know Lochlan will eventually need a wheelchair, but vamorolone could prolong the time he has to walk.
Article content
“It will give him more time to be a kid, and more time to ride a bike, and more time to just stay on his feet and walk around and play sports,” she said.
Article content
“Even if it gives him just a few more years, it would be life-changing for him.”
Article content
With deflazacort expected to run out in the spring, the Booth family is pleading with the B.C. government to speed up the approval process and fund vamorolone.
Article content
“It’s so frustrating watching this approval and funding process go so slow. You’re watching your boy thinking, ‘How much longer do you have to walk? Will this be available and accessible to us before you lose your ability to walk?’”
Article content

Article content
A much cheaper steroid drug called prednisone is also available, but it comes with horrible side effects, such as weight gain, mood changes and sleep issues, said Kasha Mitton, a Kamloops mother whose 14-year-old son Jude has Duchenne.
